Literature DB >> 24234185

Radiofrequency ablation of thoracic tumours: lessons learned with ablation of 100 lesions.

Irene Garetto1, Marco Busso, Diego Sardo, Claudia Filippini, Federica Solitro, Maria Luisa Grognardi, Andrea Veltri.   

Abstract

PURPOSE: Our aim was to analyse the results of our first 100 radiofrequency ablation (RFA) procedures, of primary (nonsmall-cell lung cancers, NSCLC) and secondary (MTS) lung cancers to assess what lessons could be learned from our experience.
MATERIALS AND METHODS: We analysed 100 lesions (mean size 23 mm) in 81 patients (25 NSCLC/56 MTS). On the basis of the clinical-radiological evolution, we analysed complete ablation (CA) versus partial ablation (PA) at the first computed tomography (CT) scan and during the follow-up (mean 23 months), time to progression (TTP) and survival. Possible predictive factors for local effectiveness and survival were sought.
RESULTS: At the first CT scan CA was obtained in 88 %; the difference between the mean diameter of lesions achieving CA and PA was significant (20 versus 38 mm; p = 0.0001). A threshold of 30 mm (p = 0.0030) and the histological type (NSCLC 75 %/MTS 94 %; p = 0.0305) were also predictive of CA. A total of 18.4 % of the CA recurred (average TTP 19 months). Survival at 1, 2 and 3 years was 84.5, 65.4 and 51.5 %, respectively. The predictors of survival at 3 years were the coexistence of other MTS (p = 0.0422) and a diameter <20 mm (p = 0.0323), but not the local effectiveness of RFA.
CONCLUSION: RFA for thoracic malignancies is accurate for lesions up to 30 mm, especially if metastatic; survival is more closely related to staging factors than to the local effectiveness of RFA.

Entities:  

Mesh:

Year:  2013        PMID: 24234185     DOI: 10.1007/s11547-013-0308-5

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  21 in total

1.  Racial differences in the treatment of early-stage lung cancer.

Authors:  P B Bach; L D Cramer; J L Warren; C B Begg
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

2.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman; Luigi Solbiati; Thomas J Vogl; Bradford J Wood; Suresh Vedantham; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

Review 3.  A systematic review of radiofrequency ablation for lung tumors.

Authors:  Jacqui C Zhu; Tristan D Yan; David L Morris
Journal:  Ann Surg Oncol       Date:  2008-03-27       Impact factor: 5.344

4.  Percutaneous radiofrequency ablation of pulmonary tumors--is there a difference between treatment under general anaesthesia and under conscious sedation?

Authors:  R T Hoffmann; T F Jakobs; A Lubienski; A Schrader; C Trumm; M F Reiser; T K Helmberger
Journal:  Eur J Radiol       Date:  2006-05-26       Impact factor: 3.528

5.  Lung tumors treated with percutaneous radiofrequency ablation: computed tomography imaging follow-up.

Authors:  Jean Palussière; Benjamin Marcet; Edouard Descat; Frédéric Deschamps; Pramod Rao; Alain Ravaud; Véronique Brouste; Thierry de Baère
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12-03       Impact factor: 2.740

Review 6.  Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes.

Authors:  Haruhiko Kondo; Takehiro Okumura; Yasuhisa Ohde; Kazuo Nakagawa
Journal:  Int J Clin Oncol       Date:  2005-04       Impact factor: 3.402

7.  Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival.

Authors:  Tristan D Yan; Julie King; Adrian Sjarif; Derek Glenn; Karin Steinke; David L Morris
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

8.  Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

Authors:  Thierry de Baère; Jean Palussière; Anne Aupérin; Antoine Hakime; Mohamed Abdel-Rehim; Michèle Kind; Clarisse Dromain; Alain Ravaud; Nathalie Tebboune; Valérie Boige; David Malka; Clarisse Lafont; Michel Ducreux
Journal:  Radiology       Date:  2006-08       Impact factor: 11.105

9.  Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates.

Authors:  Hiran C Fernando; Alberto De Hoyos; Rodney J Landreneau; Sebastian Gilbert; William E Gooding; Percival O Buenaventura; Neil A Christie; Chandra Belani; James D Luketich
Journal:  J Thorac Cardiovasc Surg       Date:  2005-03       Impact factor: 5.209

10.  Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients.

Authors:  Caroline J Simon; Damian E Dupuy; Thomas A DiPetrillo; Howard P Safran; C Alexander Grieco; Thomas Ng; William W Mayo-Smith
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

View more
  6 in total

1.  Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.

Authors:  Ya Ruth Huo; Derek Glenn; Winston Liauw; Mark Power; Jing Zhao; David L Morris
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

2.  Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors.

Authors:  Okan Akhan; Ezgi Güler; Devrim Akıncı; Türkmen Çiftçi; Ilgaz Çağatay Köse
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

3.  CT perfusion imaging can detect residual lung tumor early after radiofrequency ablation: a preliminary animal study on both tumoral and peri-tumoral region assessment.

Authors:  Zenghui Cheng; Yixue Wang; Min Yuan; Jianxiao Liang; Yanling Feng; Yuxin Shi; Zhiyong Zhang; Fei Shan
Journal:  J Thorac Dis       Date:  2022-01       Impact factor: 2.895

Review 4.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

5.  Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies: efficacy, safety and predictive factors.

Authors:  Tina Streitparth; Denis Schumacher; Robert Damm; Bjoern Friebe; Konrad Mohnike; Ortrud Kosiek; Maciej Pech; Jens Ricke; Florian Streitparth
Journal:  Oncotarget       Date:  2018-01-18

6.  Use of microwave ablation in the treatment of patients with multiple primary malignant tumors.

Authors:  Yue Han; Na Shao; Xiaoming Xi; Xuezhi Hao
Journal:  Thorac Cancer       Date:  2017-05-31       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.